Log in or Sign up for Free to view tailored content for your specialty!
Viral Hepatitis News

Viral hepatitis elimination requires equitable public health approach
Viral hepatitis is a major danger to public health. According to WHO’s 2024 Global Hepatitis Report, viral hepatitis deaths increased from 1.1 million in 2019 to 1.3 million in 2022, rates now similar to tuberculosis.
Chronic HBV treatment with xalnesiran plus immunomodulator confers highest HBsAg loss

Treatment with xalnesiran, a small interfering RNA molecule, plus an immunomodulator resulted in hepatitis B surface antigen loss among adults with chronic HBV infection, according to a study published in The New England Journal of Medicine.
CDC: Heplisav-B joins recommended HBV vaccine options for pregnant patients

Data from a postlicensure study support the CDC’s recommendation that Heplisav-B can now be administered to pregnant persons needing hepatitis B vaccination, as its use did not appear to increase risk for major birth defects or miscarriage.
Log in or Sign up for Free to view tailored content for your specialty!
HCC incidence nearly 5-times higher among HBV, HDV coinfected patients with cirrhosis

Incidence of hepatocellular carcinoma was significantly higher among cirrhotic patients coinfected with hepatitis B and D viruses compared with those with HBV alone, with researchers suggesting HDV “plays a direct role” in HCC occurrence.
‘Only one in six’ veterans with chronic HBV finish HDV testing despite severe disease risk

Among veterans with chronic hepatitis B virus infection, rates of hepatitis D virus testing were low and those with concurrent infection were at greater risk for cirrhosis and hepatic decompensation, according to study results.
Combination PEG-INF a-2b therapy achieves higher HBsAg loss in HBV-infected children

SAN DIEGO — Combination therapy with peginterferon alfa-2b and nucleos(t)ide analogues resulted in significantly higher hepatitis B surface antigen loss vs. monotherapy in children with HBV, especially among those aged younger than 7 years.
VIDEO: Combination tobevibart, elebsiran induces ‘rapid virologic suppression’ in HDV
SAN DIEGO — Combination tobevibart and elebsiran led to “profound and rapid virologic suppression” as well as normalization of alanine aminotransferase at week 24 in chronic hepatitis D virus infection, according to preliminary data.
VIDEO: HBsAg loss with tobevibart, elebsiran combination ‘highly promising’ in chronic HBV
SAN DIEGO — Treatment with combination tobevibart and elebsiran led to hepatitis B surface antigen loss among 39% of patients with chronic HBV and low baseline HBsAg, which rose to 46% by adding pegylated interferon-alfa, data showed.
Resuming antiviral therapy after withdrawal does not affect HBsAG seroclearance in HBV

SAN DIEGO — Retreatment with nucleos(t)ide analogue therapy for relapse after withdrawal did not affect hepatitis B surface antigen seroclearance among patients with chronic HBV infection, according to a researcher at The Liver Meeting.
‘Change the HDV narrative’: A call to heighten awareness, prioritize early detection

As you read these words, you may be learning for the first time about hepatitis delta virus — a lesser-known type of hepatitis that is potentially life-threatening.
-
Headline News
Veterinarians had undetected bird flu infections, but such cases are rare, CDC says
February 19, 20252 min read -
Headline News
Semaglutide may raise risk for form of optic neuropathy in adults with type 2 diabetes
February 20, 20253 min read -
Headline News
CDC disease detectives ‘remain in their positions,’ agency says
February 20, 20253 min read
-
Headline News
Veterinarians had undetected bird flu infections, but such cases are rare, CDC says
February 19, 20252 min read -
Headline News
Semaglutide may raise risk for form of optic neuropathy in adults with type 2 diabetes
February 20, 20253 min read -
Headline News
CDC disease detectives ‘remain in their positions,’ agency says
February 20, 20253 min read